7 Things to Know About Unique Lymphoma Drug Tafasitamab
The US Food and Drug Administration (FDA) recently licensed tafasitamab-cxix (Monjuvi) in combination with lenalidomide for the medication of adults with relapsed or refractory diffuse sizable B-cell lymphoma (DLBCL) now not in any other case specified, including DLBCL coming up…